All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD19 TCR-fused Antigen Binding Receptor (TCR-ABR) CAR is constructed for the engineering of T cells to target Mouse CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv (XW-63) of anti-CD19 antibody linked to TCRα subunit. The vector product was designed for the discovery and development of cellular therapy against Chronic lymphocytic leukemia (CLL). The TCR-ABR can effectively reprogram an intact TCR complex to recognize tumor surface antigens. TCR-ABR-T cells are shown to engage the signaling capacity of the entire TCR complex in an HLA-independent manner.
There are currently no customer reviews or questions for Anti-CD19 TCR-ABR (scFv-TCRα, XW-63) CAR Plasmid, pCDCAR1 (XS-1122-YF983). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION